A child presents with bladder exstrophy and chronic renal failure. The muscle relaxant of choice to be used during surgery of exstrophy in this child is
First, I need to recall what bladder exstrophy is. It's a congenital condition where the bladder is outside the body, so surgery is necessary. Now, the key here is the chronic renal failure. That means the child's kidneys aren't functioning well, which affects drug metabolism and excretion. Muscle relaxants are often eliminated via the kidneys, so drugs that are primarily excreted by the kidneys would be problematic here.
The options aren't given, but common muscle relaxants include non-depolarizing ones like rocuronium, vecuronium, pancuronium, and depolarizing ones like succinylcholine. Since the question is about renal failure, I need to think about which of these are metabolized by the liver versus the kidneys.
Succinylcholine is a depolarizing agent. Its metabolism is via plasma cholinesterase, so renal failure doesn't affect it much. However, in some cases of renal failure, especially with chronic use, there might be pseudocholinesterase deficiency, but that's less common. But the problem here is the need for a non-depolarizing agent that's not dependent on renal excretion.
Non-depolarizing agents like rocuronium are mainly excreted by the liver. Vecuronium and pancuronium have some renal excretion. Pancuronium is mostly excreted by the kidneys, so in renal failure, its duration would be prolonged, making it a bad choice. Vecuronium has some hepatic metabolism but also some renal. Rocuronium is better because it's more hepatically cleared.
So the muscle relaxant of choice in renal failure would be one that's primarily hepatically metabolized. So the correct answer would be rocuronium. The other options (vecuronium, pancuronium) are excreted via the kidneys, so they're contraindicated. Succinylcholine might be considered, but non-depolarizers are generally preferred for longer surgeries. The clinical pearl here is that in renal failure, avoid drugs with significant renal excretion. High-yield fact: rocuronium is the preferred agent in renal failure because of hepatic metabolism.
**Core Concept**
This question tests the pharmacological principles of neuromuscular blocking agents (NMBAs) in patients with renal impairment. Non-depolarizing NMBAs are metabolized and excreted via hepatic or renal pathways, and their use in renal failure requires selecting agents with minimal renal dependency.
**Why the Correct Answer is Right**
Rocuronium is primarily metabolized by the liver (via ester hydrolysis) and excreted in bile, making it suitable for patients with renal failure. Its elimination is less affected by reduced kidney function compared to agents with significant renal excretion. This ensures predictable neuromuscular blockade duration without prolonged effects from drug accumulation.
**Why Each Wrong Option is Incorrect**
**Option B:** Vecuronium has partial renal excretion (30-40%), leading to prolonged duration and risk of residual paralysis in renal failure.
**Option C:** Pancuronium is predominantly renally excreted